Publikationen in Zusammenarbeit mit Forschern von Universitat Autònoma de Barcelona (4)

2015

  1. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for patients with newly diagnosed multiple myeloma

    Leukemia and Lymphoma, Vol. 56, Núm. 2, pp. 415-419

  2. Critical analysis of the stringent complete response in multiple myeloma: Contribution of sFLC and bone marrow clonality

    Blood, Vol. 126, Núm. 7, pp. 858-862

2013

  1. Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach

    Biology of Blood and Marrow Transplantation, Vol. 19, Núm. 1, pp. 69-74

2009

  1. Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: A phase II trial

    Leukemia and Lymphoma, Vol. 50, Núm. 2, pp. 216-222